Table 2.
Association between MET and PD-L1 expressions and clinicopathological characteristics in PDAC patients
| Characteristics | MET and PD-L1 | MET and PD-L1 | P value |
|---|---|---|---|
| low expression (N = 44) | high expression (N = 49) | ||
| Gender | 0.523 | ||
| Male | 28 (50 %) | 28 (50 %) | |
| Female | 16 (42.1 %) | 21 (57.9 %) | |
| Age | 0.432 | ||
| ≤ 60 years | 14 (53.8 %) | 12 (46.2 %) | |
| > 60 years | 30 (44.8 %) | 37 (55.2 %) | |
| BMI | 0.664# | ||
| < 18.5 | 4 (40 %) | 6 (60 %) | |
| 18.5–23.9 | 31 (50.8 %) | 30 (49.2 %) | |
| > 23.9 | 9 (40.9 %) | 13 (59.1 %) | |
| Tumor location status | 0.127 | ||
| Head and neck | 35 (52.2 %) | 32 (47.8 %) | |
| Body and tail | 9 (34.6 %) | 17 (65.4 %) | |
| Tumor size status | 0.501# | ||
| ≤ 2 cm | 5 (50 %) | 5 (50 %) | |
| 2 < n ≤ 4 cm | 32 (50.8 %) | 31 (49.2 %) | |
| > 4 cm | 7 (35 %) | 13 (65 %) | |
| Lymph nodes involvement | 0.034 | ||
| No | 21 (61.8 %) | 13 (38.2 %) | |
| Yes | 23 (39 %) | 36 (61 %) | |
| TNM stage | 0.020# | ||
| I | 15 (75 %) | 5 (25 %) | |
| II | 27 (39.7 %) | 41 (60.2 %) | |
| III-IV | 2 (40 %) | 3 (60 %) | |
| Tumor differentiation | 0.869# | ||
| Well differentiated | 9 (60 %) | 6 (40 %) | |
| Moderately differentiated | 18 (42.9 %) | 24 (57.1 %) | |
| Poorly differentiated | 17 (47.2 %) | 19 (52.8 %) | |
| CA199 | 0.575 | ||
| ≤ 37 | 7 (41.2 %) | 10 (58.8 %) | |
| > 37 | 37 (48.7 %) | 39 (51.3 %) | |
| CA125 | 0.597 | ||
| ≤ 35 | 33 (45.8 %) | 39 (54.2 %) | |
| > 35 | 11 (52.4 %) | 10 (47.6 %) | |
| CEA | 0.196 | ||
| ≤ 5 | 30 (52.6 %) | 27 (47.4 %) | |
| > 5 | 14 (38.9 %) | 22 (61.1 %) |
Data are presented as numbers and percentages (in parentheses) based on the total number of patients with tumors expressing high and low MET and PD-L1 levels. P values were determined using Chi-square tests. #, using Fisher’s exact test; P < 0.05, statistically significant